Results 111 to 120 of about 1,583,699 (313)
Dermatology and TherapyIntroduction Deucravacitinib demonstrated superior efficacy to apremilast in patients with moderate to severe plaque psoriasis in the POETYK PSO-1 and PSO-2 clinical trials. In the study reported here, we aimed to determine the overall 52-week cumulative
April W. Armstrong +6 more
doaj +1 more source
Open Access Publishing in Particle Physics: A Brief Introduction for the non-Expert [PDF]
arXiv, 2007 Open Access to particle physics literature does not sound particularly new or exciting, since particle physicists have been reading preprints for decades, and arXiv.org for 15 years. However new movements in Europe are attempting to make the peer-reviewed literature of the field fully Open Access.
arxiv
Molecular Oncology, EarlyView.Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink +6 more
wiley +1 more source
Can scientists and their institutions become their own open access publishers? [PDF]
arXiv, 2017 This article offers a personal perspective on the current state of academic publishing, and posits that the scientific community is beset with journals that contribute little valuable knowledge, overload the community's capacity for high-quality peer review, and waste resources.
arxiv
Emerging Infectious Diseases, 2004 An Open Access Publishing Conference was convened in Atlanta, Georgia, on January 7, 2004, by the libraries of the Centers for Disease Control and Prevention (CDC) and Emory University. Open Access is an emerging publishing model for peer-reviewed scientific research in which authors and their publishers grant free access to their work as long as the ...
Jocelyn A. Rankin, Sandra G. Franklin
openaire +4 more sources
Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells
Molecular Oncology, EarlyView.In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi +3 more
wiley +1 more source
Molecular Oncology, EarlyView.Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker +14 more
wiley +1 more source
Open-access endoscopy service for general practitioners. [PDF]
, 1979 V Moshakis
openalex +1 more source
Molecular Oncology, EarlyView.In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen +13 more
wiley +1 more source